Treatment of Neuromuscular Channelopathies: Current Concepts and Future Prospects

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 607-612

  Cleland, James C ^a,b   Griggs, Robert C ^b  

^a WAIKATO HOSPITAL   (New Zealand)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

channelopathy; electrophysiology; ion channel; Therapy

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CROMAKALIM; DICLOFENAMIDE; MEXILETINE; PHENYTOIN; PLACEBO; PROPAFENONE;

ARTICLE; CHLORIDE CONDUCTANCE; EXON; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; HYPOKALEMIC PERIODIC PARALYSIS; MUSCLE CHANNELOPATHY; MYOTONIA; MYOTONIC DYSTROPHY; NONHUMAN; PARALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RNA SPLICING; THOMSEN DISEASE;

ANIMALS; CHANNELOPATHIES; GENE THERAPY; HUMANS; ION CHANNELS; MYOTONIC DISORDERS;

EID: 53249105761     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.09.001     Document Type: Article

References (39)

1. Colding-Jørgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve 32 (2005) 19-34
2. Jurkatt-Rott K., and Lehmann-Horn F. Muscle channelopathies and critical points in functional and genetic studies. J Clin Invest 115 (2005) 2000-2009
3. +: Insights into resting potential abnormalities in hypokalemic paralysis. Muscle Nerve 37 (2008) 326-337
4. Cleland J.C., and Griggs R.C.G. Channelopathies of the nervous system. In: Gilman S. (Ed). Neurobiology of Disease (2007), Elsevier Academic Press, Burlington, MA 319-332
5. Venance S.L., Herr B.E., and Griggs R.C. Challenges in the design and conduct of therapeutic trials in channel disorders. Neurotherapeutics 4 (2007) 199-204
6. Tawil R., McDermott M.P., Brown Jr. R., et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working group on periodic paralysis. Ann Neurol 47 (2000) 46-53
7. +-deficient rats. FASEB J 18 (2004) 760-761
8. Riggs J.E., Griggs R.C., and Moxley R.T. Dissociation of glucose and potassium arterial-venous differences across the forearm by acetazolamide: a possible relationship to acetazolamide's beneficial effect in hypokalemia periodic paralysis. Arch Neurol 41 (1984) 35-38
9. Riggs J.E., Griggs R.C., Moxley R.T., and Lewis E.D. Acute effects of acetazolamide in hyperkalemic periodic paralysis and in normals. Neurology 31 (1981) 725-729
10. + conductance improves the in vitro contraction force of skeletal muscle in hypokalemic periodic paralysis. Muscle Nerve 13 (1990) 451-457
11. Lin S.-H., Chiu J.-S., Hsu C.-W., and Chau T. A simple and rapid approach to hypokalemic paralysis. Am J Emerg Med 21 (2003) 487-491
12. Gallant E.M. Barium-treated mammalian skeletal muscle: similarities to hypokalemic periodic paralysis. J Physiol 335 (1983) 577-590
13. + current. Neurology 53 (1999) 1556-1563
14. Abbot G.W., Butler M.H., and Goldstein S.A.N. Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis. FASEB J 20 (2006) 293-301
15. Tricarico D., Servidei S., Tonali P., Jurkat-Rott K., and Conte Camerino D. Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis. J Clin Invest 103 (1999) 675-682
16. Osborne R.J., and Thornton C.A. RNA-dominant diseases. Human Mol Genet 15 (2006) 162-169
17. Takahashi M.P., and Cannon S.C. Mexilitene block of disease-associated muations in S6 segments of the human skeletal muscle Na+ channel. J Physiol 537 (2001) 701-714
18. Alfonsi E., Merlo I.M., Tonini M., Ravaglia S., Brugnoni R., Gozzini A., and Moglia A. Efficacy of propafenone in paramytonia congenita. Neurology 68 (2007) 1080-1081
19. Willoughby J.O., Pope K.J., and Eaton V. Nicotine as an anti-epileptic agent in ADNFLE: an n-of-one study. Epilepsia 44 (2003) 1238-1240
20. Zucker D.R., Schmid C.H., McIntosh M.W., D'Agostino R.B., Selker H.P., and Lau J. Combining single patient (n-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 50 (1997) 401-410
21. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., and Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117 (2007) 3952-3957
22. Rogers C.S., Vanoye C.G., Sullenger B.A., and George Jr. A.L. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J Clin Invest 110 (2002) 1783-1789
23. Argov Z., McKee D., Agus S., et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69 (2007) 699-700
24. Arimura K., Arimura Y., Ng A.R., Sakoda S.-I., and Higuchi I. Muscle membrane excitability after exercise in thyrotoxic periodic paralysis and thyrotoxicosis without periodic paralysis. Muscle Nerve 36 (2007) 784-788
25. Zhang J., Bendahhou S., Sanguinetti J., and Ptacek L.J. Functional consequence of chloride channel gene (CLCN1) mutations causing myotonia congenita. Neurology 54 (2000) 937-942
26. Papponen H., Nissinen M., Kaisto T., Myllylä V.V., Myllylä R., and Metsikkö K. F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulum export of the muscle-specific chloride channel CLC-1. Muscle Nerve 37 (2008) 317-325
27. Wang Y., Bartlett C., Loo T.W., and Clarke D.M. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70 (2006) 297-302
28. Kinali M., Jungbluth H., Eunson L.H., et al. Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord 14 (2004) 689-693
29. Allen D.C., Arunachalam R., and Mills K.R. Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy. Muscle Nerve 37 (2008) 14-22
30. Wuttke T.V., Jurkat-Rott K., Paulus W., Garncarek M., Lehmann-Horn F., and Lerche H. Peripheral nerve hyperexcitability due to dominant negative KCNQ2 mutations. Neurology 69 (2007) 2045-2053
31. Sansone V., and Tawil R. Management and treatment of Andersen-Tawil syndrome. Neurotherapeutics 4 (2007) 233-237
32. Vicart S., Sternberg D., Fontaine B., and Meola G. Human skeletal muscle sodium channelopathies. Neurol Sci 26 (2005) 194-202
33. Waxman S.G., and Dib-Hajj S.D. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 57 (2005) 785-788
34. Tsujino A., Maertens C., Ohno K., et al. Myasthenic syndrome caused by mutation of the SCN4A channel. Proc Natl Acad Sci 100 (2003) 7377-7382
35. Engel A.G., Ohno K., and Sine S.M. Congenital myasthenic syndromes. In: Engel A.G. (Ed). Myasthenia gravis and myasthenic disorders (1999), Oxford University Press, New York, NY 251-297
36. 2+ in malignant hyperthermia and central core disease. Biochem Biophys Res Commun 322 (2004) 1256-1266
37. Vernino S., and Lennon V.A. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular excitability. Muscle Nerve 26 (2002) 702-707
38. Newsom-Davis J., and Lang B. The Lambert-Eaton myasthenic syndrome. In: Engel A.G. (Ed). Myasthenia Gravis and Related Disorders (1999), Oxford University Press, New York, NY 205-228
39. Teener J.W., and Rich M.M. Dysregulation of sodium channel gating in critical illness myopathy. J Muscle Res Cell Motil 27 (2006) 291-296